Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • 4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    • News

  • Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    • News

  • March 2025 quarter CPI above expectations – but RBA cut still likely
    March 2025 quarter CPI above expectations – but RBA cut still likely
    • News

  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    • News

  • PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    • News

  • Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    • News

  • Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    • News

  • Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    • News

  • Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    • News

  • Spenda Secures $3M Term Loan to Accelerate Growth
    Spenda Secures $3M Term Loan to Accelerate Growth
    • News

Archer makes major advances towards lab-on-a-chip technology

  • In News
  • November 3, 2023
  • Alinda Gupta
Archer makes major advances towards lab-on-a-chip technology

A semiconductor company with a quantum computing and medical diagnostics focus, Archer Materials Limited (ASX: AXE), has announced a notable development in its advanced Biochip graphene field effect transistor (gFET) technology.

Archer has successfully demonstrated multiplexing readout capabilities for its Biochip, i.e. they have shown the device can make sense of multiple liquid samples arriving at the sensors of the chip in order to allow the potential detection of numerous diseases in one go, saving time and money.

Archer integrated four advanced gFETs as sensors into its Biochip platform, enabling single-device multiplexing. This breakthrough paves the way for simultaneous testing of multiple diseases on a single chip, a challenging feat that is made possible thanks to the single atom thick material called graphene.

CEO of Archer, Dr. Mohammad Choucair, commented, “Archer is now able to demonstrate readout, or a signal, from multiple graphene sensors and liquid samples coming from the Biochip, which is a step-change in advancing towards the potential to sense multiple disease samples at once on a single chip.

“The progress made by the Archer team to demonstrate multiplex detection, and the support of our commercial foundry partners in the manufacture of Archer’s Biochip devices, will be applied towards the function and operation of the Biochip in targeting biologically relevant molecules.”

Archer’s biochip innovation aims to integrate gFETs into advanced fluidic systems, creating miniaturised lab-on-a-chip platforms for medical diagnostics. It could transforms disease detection, which otherwise boasts a high emotional and financial cost.

One of the key advancements for Archer’s biochip is the new hardware and software systems they have designed and developed to read out signals from the gFET sensors simultaneously, marking a major improvement over the previous generation of the Biochip system, which could only activate one sensor at a time.

Moreover, the new Biochip system features automated hands-free operation, integrating liquid handling automation and data acquisition. Archer states its “software offers real-time display of single and time-series measurements for all four gFET sensors simultaneously”.

Dr. Choucair noted, “Moving testing for diseases from the lab onto a chip has the potential to create better access to healthcare for those who might not have it, thereby improving patient outcomes.”

In addition to its Biochip endeavours, Archer Materials is making progress with its 12CQ (pronounced one-two-cee-que) quantum chip technology, particularly in the design and validation of qubit control and readout technology and associated engineering processes and measurements required for quantum chip operation and function. These developments are aimed at making quantum computing more accessible in everyday devices.

Furthermore, Archer is strengthening its relationships with global semiconductor foundry partners to deliver its chips using a streamlined ‘fabless’ commercialisation model. During Q1 FY24, Archer engaged with several tier-one foundry manufacturers in Taiwan and Europe to secure future semiconductor product manufacturing capabilities and support technology development.

This “included obtaining device design kits and planning for preliminary device design validations for quantum and biochip technologies, including multi-project wafers (MPW) and whole wafer runs.”

As of the end of the quarter, Archer Materials reported $21.3 million in cash, with a cash burn of just $1.9 million, primarily driven by its technology development efforts and staff costs. As it addresses health and tech inequity, Archer is poised for growth.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • 12cq
  • archer materials
  • asx: axe
  • biochip
  • gFET
  • medical diagnostics
  • Mohammad Choucair
  • semiconductor
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.